Autolus Therapeutics plc (NASDAQ:AUTL) is Syncona Portfolio Ltd’s Largest Position

Syncona Portfolio Ltd trimmed its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 10.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,640,720 shares of the company’s stock after selling 1,913,904 shares during the quarter. Autolus Therapeutics comprises about 73.8% of Syncona Portfolio Ltd’s holdings, making the stock its largest position. Syncona Portfolio Ltd owned 0.06% of Autolus Therapeutics worth $39,106,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. bought a new stake in Autolus Therapeutics during the fourth quarter worth about $611,000. Wellington Management Group LLP lifted its stake in Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after purchasing an additional 6,330,392 shares during the last quarter. FMR LLC lifted its stake in Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after purchasing an additional 5,478,706 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Autolus Therapeutics during the third quarter worth about $708,000. Finally, GSA Capital Partners LLP bought a new stake in Autolus Therapeutics during the third quarter worth about $1,082,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

AUTL opened at $2.06 on Thursday. Autolus Therapeutics plc has a one year low of $1.68 and a one year high of $6.63. The business has a 50 day simple moving average of $2.15 and a two-hundred day simple moving average of $3.09. The firm has a market capitalization of $548.15 million, a price-to-earnings ratio of -1.70 and a beta of 2.07.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on AUTL shares. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.